Clinical Trials

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Breast Neoplasms

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Available

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT04313075 2025-07-15

A Compassionate Use Study of Leronlimab in Breast Cancer

Triple Negative Breast Neoplasms

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

HER2-positive Breast Cancer

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05134922 2025-03-21

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Available

Breast Neoplasm Malignant Female

NCT03133988 2025-02-14

Margetuximab Expanded Access Program

HER2-positive Breast Cancer

NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

NCT03763604 2024-12-16

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Breast Neoplasms

NCT04395508 2022-07-05

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

HER2-positive Breast Cancer

NCT03123211 2022-05-24

Expanded Access to Veliparib

Triple Negative Breast Neoplasms

NCT05108740 2021-12-09

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Breast Neoplasms

NCT04320693 2021-08-19

Expanded Access for IMMU-132

Triple Negative Breast Neoplasms

NCT03706573 2021-07-19

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Breast Neoplasms

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

NCT02142868 2018-12-21

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Advanced Breast Cancer (Female)

NCT03067935 2018-05-21

Individual Patient Expanded Access-Glembatumumab Vedotin

Metastatic gpNMB Expressing Triple Negative Breast Cancer

NCT02792725 2017-10-31

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Breast Neoplasms

NCT01120561 2017-02-15

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

NCT00338247 2016-04-06

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

NCT01240421 2015-05-22

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Breast Neoplasms

NCT01130259 2013-09-17

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer